The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology.

IDH -mutant gliomas represent a rare subset of brain tumors, affecting approximately 12% to 20% of adult patients with glioma ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

She identified 2 primary frontiers for clinical investigation: the eradication of persistent cancer cells and the management ...

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion-positive NSCLC, signaling a ...

Decreases in circulating tumor DNA (ctDNA) within the first month of immune checkpoint inhibitor (ICI) therapy were strongly ...

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...